Aclaris Therapeutics (ACRS) Competitors $1.57 +0.02 (+1.29%) Closing price 04:00 PM EasternExtended Trading$1.54 -0.03 (-1.59%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. NAGE, UPB, DAWN, KALV, AMLX, AVBP, GYRE, STOK, ATAI, and PHARShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Niagen Bioscience (NAGE), Upstream Bio (UPB), Day One Biopharmaceuticals (DAWN), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), Gyre Therapeutics (GYRE), Stoke Therapeutics (STOK), atai Life Sciences (ATAI), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Niagen Bioscience Upstream Bio Day One Biopharmaceuticals KalVista Pharmaceuticals Amylyx Pharmaceuticals ArriVent BioPharma Gyre Therapeutics Stoke Therapeutics atai Life Sciences Pharming Group Aclaris Therapeutics (NASDAQ:ACRS) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders & institutionals believe in ACRS or NAGE? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ACRS or NAGE more profitable? Niagen Bioscience has a net margin of 15.24% compared to Aclaris Therapeutics' net margin of -732.42%. Niagen Bioscience's return on equity of 25.53% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-732.42% -30.73% -22.74% Niagen Bioscience 15.24%25.53%16.82% Which has better earnings & valuation, ACRS or NAGE? Niagen Bioscience has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M9.08-$132.07M-$1.39-1.13Niagen Bioscience$99.60M7.60$8.55M$0.1756.53 Do analysts prefer ACRS or NAGE? Aclaris Therapeutics presently has a consensus target price of $8.71, indicating a potential upside of 455.05%. Niagen Bioscience has a consensus target price of $13.22, indicating a potential upside of 37.57%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ACRS or NAGE? Aclaris Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Does the media prefer ACRS or NAGE? In the previous week, Niagen Bioscience had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 10 mentions for Niagen Bioscience and 9 mentions for Aclaris Therapeutics. Niagen Bioscience's average media sentiment score of 0.52 beat Aclaris Therapeutics' score of 0.46 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNiagen Bioscience beats Aclaris Therapeutics on 11 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.84M$2.51B$5.48B$9.57BDividend YieldN/A1.78%4.00%4.18%P/E Ratio-1.1319.6629.8825.14Price / Sales9.08679.55442.11104.25Price / CashN/A165.0335.9458.58Price / Book1.094.198.105.59Net Income-$132.07M$31.61M$3.26B$265.48M7 Day Performance2.61%0.24%-0.09%-0.41%1 Month Performance7.53%6.25%4.19%1.39%1 Year Performance31.93%6.10%29.38%24.69% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.009 of 5 stars$1.57+1.3%$8.71+455.1%+27.0%$167.84M$18.72M-1.13100News CoverageEarnings ReportNAGENiagen Bioscience1.4741 of 5 stars$9.69+4.0%$13.22+36.4%N/A$734.13M$99.60M57.00120News CoverageEarnings ReportGap UpUPBUpstream Bio1.7658 of 5 stars$14.34+5.2%$56.50+294.0%N/A$733.21M$2.37M0.0038News CoverageEarnings ReportGap UpHigh Trading VolumeDAWNDay One Biopharmaceuticals2.6519 of 5 stars$7.10-1.8%$29.00+308.5%-55.8%$732.85M$131.16M-10.0060News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionKALVKalVista Pharmaceuticals3.7832 of 5 stars$13.57-6.9%$26.29+93.7%-1.4%$728.33MN/A-3.68100AMLXAmylyx Pharmaceuticals2.7741 of 5 stars$7.99-2.0%$11.75+47.1%+315.7%$726.50M$87.37M-2.57200Earnings ReportGap DownAVBPArriVent BioPharma1.6276 of 5 stars$20.93-1.2%$39.29+87.7%-11.0%$724.62MN/A-5.5540Upcoming EarningsGYREGyre Therapeutics0.0162 of 5 stars$7.81+2.2%N/A-34.9%$716.31M$105.76M390.7040News CoverageUpcoming EarningsGap UpSTOKStoke Therapeutics3.9612 of 5 stars$12.81-2.2%$25.80+101.4%-7.4%$715.22M$36.56M16.22100Positive NewsATAIatai Life Sciences3.0318 of 5 stars$3.33-6.7%$8.67+160.3%+205.8%$715.21M$310K-3.6680Upcoming EarningsShort Interest ↑PHARPharming Group2.9931 of 5 stars$10.00-2.5%$30.00+200.0%+51.9%$702.96M$297.20M-50.00280Earnings Report Related Companies and Tools Related Companies Niagen Bioscience Competitors Upstream Bio Competitors Day One Biopharmaceuticals Competitors KalVista Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors ArriVent BioPharma Competitors Gyre Therapeutics Competitors Stoke Therapeutics Competitors atai Life Sciences Competitors Pharming Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts